| 1 |
35094535 | How we treat HR-positive, HER2-negative early breast cancer. | 2022 Mar |
1 |
| 2 |
35135362 | Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer. | 2022 Feb 8 |
1 |
| 3 |
35169388 | Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. | 2022 Feb |
1 |
| 4 |
32710211 | MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. | 2021 Mar |
1 |
| 5 |
33280445 | Preclinical discovery and development of abemaciclib used to treat breast cancer. | 2021 May |
1 |
| 6 |
33968263 | ESMO 2020: highlights in breast cancer. | 2021 Apr 30 |
1 |
| 7 |
34690920 | Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature. | 2021 |
1 |
| 8 |
32582803 | Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells. | 2020 Jan |
1 |
| 9 |
32835580 | Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells. | 2020 Sep 1 |
1 |
| 10 |
33116117 | Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma. | 2020 Oct 28 |
1 |
| 11 |
31464525 | Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. | 2019 Oct |
1 |
| 12 |
29429832 | Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships. | 2018 Mar 1 |
1 |
| 13 |
29716919 | Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo. | 2018 Aug 15 |
1 |
| 14 |
30014236 | Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature. | 2018 Nov |
1 |
| 15 |
30165341 | Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors. | 2018 Sep 5 |
1 |
| 16 |
27748766 | Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. | 2017 Apr 20 |
1 |
| 17 |
27816545 | Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. | 2017 Jan 15 |
1 |
| 18 |
29125595 | Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer. | 2017 Nov 6 |
2 |
| 19 |
26896604 | Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. | 2016 Jan |
1 |
| 20 |
26909611 | The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. | 2016 Mar 22 |
3 |
| 21 |
26995305 | Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. | 2016 May |
1 |
| 22 |
27312735 | Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. | 2016 Aug |
1 |
| 23 |
27493615 | Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. | 2016 Jun |
1 |
| 24 |
26726315 | Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors. | 2015 |
2 |
| 25 |
24795392 | Molecular pathways: CDK4 inhibitors for cancer therapy. | 2014 Jul 1 |
1 |
| 26 |
24850847 | Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. | 2014 Jul 15 |
1 |
| 27 |
24919854 | Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. | 2014 Oct |
3 |
| 28 |
25122067 | The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. | 2014 Oct |
3 |